{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:54:04Z","timestamp":1777910044228,"version":"3.51.4"},"reference-count":101,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:p>\n                    Uveitis remains one of the leading causes of blindness worldwide, with different etiologies requiring separate approaches to treatment. For over a decade, oral, topical, and local injection of corticosteroids as well as systemic conventional disease-modifying antirheumatic drugs (DMARDs) have remained the most effective treatment for noninfectious uveitis (NIU). Systemic administration of antitumor necrosis factor-\u03b1 and other biological DMARDs have been used for treating cases that responded inadequately to conventional treatments. Unfortunately, some refractory patients still suffer from frequent attacks despite the combination of multiple treatments. Recently, there has been promising evidence for Janus kinase (JAK) inhibitors as the next-generation therapy for NIU. The JAK\/signal transducers and activators of the transcription (STAT) signaling pathway mediate the downstream events involved in immune fitness, tissue repair, inflammation, apoptosis, and adipogenesis by binding various ligands, such as cytokines, growth hormones, and growth factors. The mutation or loss of JAK\/STAT components is implicated in autoimmune diseases, thus inhibition of such pathways has been an important area of research in therapeutic development.\n                    <jats:sup>1<\/jats:sup>\n                    In this review, we provide a comprehensive overview of the efficacy and safety of JAK inhibitors for the management of NIU, with evidence from current trials and case reports.\n                  <\/jats:p>","DOI":"10.1089\/jop.2024.0100","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T10:01:16Z","timestamp":1727172076000},"page":"44-53","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis"],"prefix":"10.1177","volume":"41","author":[{"given":"Hui Yu","family":"Juan","sequence":"first","affiliation":[{"name":"Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shwu-Jiuan","family":"Sheu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan."},{"name":"Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6346-8485","authenticated-orcid":false,"given":"De-Kuang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan."},{"name":"Department of Ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_3_5_3_2","volume-title":"StatPearls","author":"Duplechain A","year":"2023","unstructured":"Duplechain A, , Conrady CD, , Patel BC, et al. Uveitis. In: StatPearls. StatPearls Publishing; 2023."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1196713"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0223-z"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.05.026"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.037226"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.4103\/meajo.MEAJO_252_16"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695904"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.339"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.001"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.027"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-021-00267-x"},{"key":"e_1_3_5_15_2","volume-title":"StatPearls","author":"Mohan S","year":"2023","unstructured":"Mohan S, , Ratra D. Intravitreal Implants. In: StatPearls. StatPearls Publishing; 2023."},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00954-6"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05862-9"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.027"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(88)90824-0"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.5.1603"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.22756"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm909"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115236"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/370151a0"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2580"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.028"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2008.07.011"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8272873"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07128.x"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8272872"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(02)00398-0"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028548"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","unstructured":"Bacon CM McVicar DW Ortaldo JR et al. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: Differential use of Janus family tyrosine kinases by IL-2 and IL-12. n.d.; doi: 10.1084\/jem.181.1.399","DOI":"10.1084\/jem.181.1.399"},{"key":"e_1_3_5_37_2","unstructured":"Ghoreschi K Laurence A O\u2019Shea JJ. Janus kinases in immune cell signaling. n.d."},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1648"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.001"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3278"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.6070"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/359674"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2015.07.003"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0042"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2022.831084"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.4161\/21623988.2014.955393"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018139"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1585"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100866"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2010.10.004"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1087061"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.19"},{"key":"e_1_3_5_55_2","volume-title":"StatPearls","author":"Padda IS","year":"2023","unstructured":"Padda IS, , Bhatt R, , Parmar M. Tofacitinib. In: StatPearls. StatPearls Publishing; 2023."},{"key":"e_1_3_5_56_2","unstructured":"Anonymous. Study Details | Tofacitinib for Inflammatory Eye Disease | ClinicalTrials.Gov. n.d. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03580343 [Last accessed: June27 2024]."},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219810"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000546"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04875-w"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1605453"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6201887"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2018.12.001"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2323671"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.784860"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000559803.24361.5e"},{"key":"e_1_3_5_67_2","volume-title":"StatPearls","author":"Ahmad A","year":"2024","unstructured":"Ahmad A, , Zaheer M, , Balis FJ. Baricitinib. In: StatPearls. StatPearls Publishing; 2024."},{"key":"e_1_3_5_68_2","unstructured":"Anonymous. Study Details | A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis | ClinicalTrials.Gov. n.d. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04088409 [Last accessed: June27 2024]."},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05651-5"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.764067"},{"key":"e_1_3_5_71_2","volume-title":"StatPearls","author":"Padda IS","year":"2024","unstructured":"Padda IS, , Bhatt R, , Patel P, et al. Upadacitinib. In: StatPearls. StatPearls Publishing; 2024."},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.12.28"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2069128"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1242"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1766-6739"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2263557"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01129-y"},{"key":"e_1_3_5_79_2","unstructured":"Anonymous. Study Details | Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis | ClinicalTrials.Gov. n.d. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03207815 [Last accessed: June27 2024]."},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2200931"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"e_1_3_5_84_2","unstructured":"Anonymous. Anx_148982_en.Pdf. n.d. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200924148982\/anx_148982_en.pdf [Last accessed: June27 2024]."},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221096713"},{"key":"e_1_3_5_86_2","unstructured":"Anonymous. FDA Approves Expanded Indication for Abrocitinib to Include Adolescents With Atopic Dermatitis. n.d. Available from: https:\/\/www.pharmacytimes.com\/view\/fda-approves-expanded-indication-for-abrocitinib-to-include-adolescents-with-atopic-dermatitis [Last accessed: June27 2024]."},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14248"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020385"},{"key":"e_1_3_5_91_2","volume-title":"StatPearls","author":"Lepe K","year":"2024","unstructured":"Lepe K, , Syed HA, , Zito PM. Alopecia Areata. In: StatPearls. StatPearls Publishing; 2024."},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41316"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.029"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.005"},{"key":"e_1_3_5_95_2","unstructured":"Anonymous. LITFULO (Ritlecitinib) Information You Need to Know.Pdf. n.d. Available from: https:\/\/pfizermedical.pfizerpro.com\/api\/vc\/en\/medical\/assets\/4ea48887-f24b-42a0-a3f1-e2eed9864a12\/LITFULO%20%28ritlecitinib%29%20Information%20You%20Need%20to%20Know.pdf [Last accessed: June27 2024]."},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100156"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42519"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300155"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21826"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad098"},{"key":"e_1_3_5_101_2","unstructured":"Anonymous. Study Details | A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis | ClinicalTrials.Gov. n.d. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05523765 [Last accessed: June27 2024]."},{"key":"e_1_3_5_102_2","unstructured":"Anonymous. Study Details | A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis | ClinicalTrials.Gov. n.d. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06431373 [Last accessed: June27 2024]."}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2024.0100","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0100","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:46:37Z","timestamp":1777646797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2024.0100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["10.1089\/jop.2024.0100"],"URL":"https:\/\/doi.org\/10.1089\/jop.2024.0100","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}